国产恩替卡韦治疗慢性乙型肝炎患者早期抗病毒的效果探讨
|
摘要
目的探讨在慢性乙型肝炎患者早期抗病毒的临床治疗中实施国产恩替卡韦治疗的临床效果。方法方便选取该院2015年1月—2018年8月接诊的28例慢性乙型肝炎展开研究,按照治疗措施的差异将其以一定的比例分为2组,给予拉米夫定联合国产阿德福韦酯治疗的为对照组,给予国产恩替卡韦治疗的为观察组,对比病毒学应答情况、血清学应答和生化学应答情况、治疗后两组患者不良反应(恶心呕吐、乏力、头昏晕眩、肾功能损害)发生率。结果病毒学应答情况:两组对比差异无统计学意义(P>0.05)。对照组和观察组患者脱氧核糖核酸(HBV-DNA)完全病毒学应答对比差异有统计学意义(P<0.05)。血清学应答和生化学应答情况:治疗第6个月,统计学不成立;治疗第12个月时对照组患者高于观察组,但是差异无统计学意义(P>0.05)。治疗第1、3、6、12个月时两组患者谷丙转氨酶(ALT)复常率组间对比,差异无统计学意义(P>0.05)。观察组恶心1例(7.1%),呕吐0例(0.0%),乏力1例(7.1%),头昏晕眩0例(0.0%),对照组恶心3例(21.4%),呕吐2例(14.2%),乏力2例(14.2%),头昏晕眩0(0.0)例,观察组不良反应发生率14.2%,对照组为50.0%。组间对比,差异有统计学意义(P<0.05)。结论在慢性乙型肝炎患者早期抗病毒的临床治疗中实施国产恩替卡韦治疗中脱氧核糖核酸(HBV-DNA)病毒学应答数值下降效果显著,值得推广。
Objective To investigate the clinical effect of domestic entecavir treatment in the early treatment of antiviral patients with chronic hepatitis B. Methods 28 cases of chronic hepatitis B admitted to our hospital from January 2015 to August 2018 were convenient selected and studied. According to the difference of treatment measures, they were divided into two groups according to the difference of treatment, and the lamivudine combined with domestic entecavir was given to the control group. The domestic entecavir for the observation group, and the virological response, serological response and biochemical response were compared. The adverse reactions(nausea and vomiting, fatigue, dizziness and the incidence of renal damage) were observed in the two groups after treatment. Results Virological response: there was no significant difference between the two groups( P>0.05); with no statistically significant difference. There was a statistically significant difference in the complete virological response of deoxyribonucleic acid(HBV-DNA) between the control group and the observation group(P<0.05). Serological response and biochemical response: There was no statistically significant difference in serum HBeAg conversion rate and HBeAg seroconversion rate between the control group and the observation group at the6 th month of treatment(P>0.05), the statistics were not established; At the time of the 12 th month, the control group was higher than the observation group, but the difference was not obvious. There was no statistically significant difference between the groups(P>0.05). At the 1 st, 3 rd, 6 th, and 12 th month of treatment, there was no statistically significant difference in the rate of alanine aminotransferase(ALT) between the two groups(P>0.05). The observation group had nausea 1 cases(7.1%), vomiting 0 cases(0.0%), fatigue 1 cases(7.1%), dizziness 0 cases(0.0%), control group nausea 3 cases(21.4%), vomiting 2 cases(14.2%), fatigue 2 cases(14.2%), dizziness 0 cases(0.0%), the incidence of adverse reactions in the observation group was 14.2%, and the control group was 50.0%. There was no statistically significant difference between the groups(P<0.05).Conclusion In the clinical treatment of early antiviral therapy in patients with chronic hepatitis B, the reduction of virological response to deoxyribonucleic acid(HBV-DNA) in domestic entecavir treatment is significant and worthy of promotion.
Objective To investigate the clinical effect of domestic entecavir treatment in the early treatment of antiviral patients with chronic hepatitis B. Methods 28 cases of chronic hepatitis B admitted to our hospital from January 2015 to August 2018 were convenient selected and studied. According to the difference of treatment measures, they were divided into two groups according to the difference of treatment, and the lamivudine combined with domestic entecavir was given to the control group. The domestic entecavir for the observation group, and the virological response, serological response and biochemical response were compared. The adverse reactions(nausea and vomiting, fatigue, dizziness and the incidence of renal damage) were observed in the two groups after treatment. Results Virological response: there was no significant difference between the two groups( P>0.05); with no statistically significant difference. There was a statistically significant difference in the complete virological response of deoxyribonucleic acid(HBV-DNA) between the control group and the observation group(P<0.05). Serological response and biochemical response: There was no statistically significant difference in serum HBeAg conversion rate and HBeAg seroconversion rate between the control group and the observation group at the6 th month of treatment(P>0.05), the statistics were not established; At the time of the 12 th month, the control group was higher than the observation group, but the difference was not obvious. There was no statistically significant difference between the groups(P>0.05). At the 1 st, 3 rd, 6 th, and 12 th month of treatment, there was no statistically significant difference in the rate of alanine aminotransferase(ALT) between the two groups(P>0.05). The observation group had nausea 1 cases(7.1%), vomiting 0 cases(0.0%), fatigue 1 cases(7.1%), dizziness 0 cases(0.0%), control group nausea 3 cases(21.4%), vomiting 2 cases(14.2%), fatigue 2 cases(14.2%), dizziness 0 cases(0.0%), the incidence of adverse reactions in the observation group was 14.2%, and the control group was 50.0%. There was no statistically significant difference between the groups(P<0.05).Conclusion In the clinical treatment of early antiviral therapy in patients with chronic hepatitis B, the reduction of virological response to deoxyribonucleic acid(HBV-DNA) in domestic entecavir treatment is significant and worthy of promotion.
引文
[1]郭立杰,王艳,王敏,等.国产恩替卡韦治疗慢性乙型肝炎患者早期抗病毒疗效观察[J].实用肝脏病杂志,2017,20(2):226-227.
[2]卢瑜.国产恩替卡韦治疗慢性乙型肝炎患者早期抗病毒疗效分析[J].中国现代药物应用,2017,11(14):107-108.
[3]刘倩,常树珍,崔速南,等.恩替卡韦对核苷类药物经治慢性乙型病毒性肝炎患者的抗病毒疗效观察[J].新医学,2017,48(3):184-187.
[4] Li W, Wang L, Liu Y, et al. Efficacy of entecavir-based rescue therapy in lamivudine-resistant chronic hepatitis B patients in China:a retrospective study[J].Die Pharmazie,2018, 73(4):223.
[5]杨冬冬.阿德福韦酯与恩替卡韦治疗HBeAg阳性慢性乙型肝炎患者临床疗效观察[J].基层医学论坛,2017,21(8):934-935.
[6]段文文,唐芙爱,卢高峰,等.恩替卡韦治疗HBeAg阴性与HBeAg阳性慢乙肝和肝硬化感染患者疗效观察[J].中国地方病防治杂志,2016,25(6):718-720.
[7]康海燕,王艳,耿惠杰,等.国产恩替卡韦治疗代偿期乙肝肝硬化患者的疗效及经济学价值研究[J].现代中西医结合杂志,2016,25(12):1333-1335.
[8]张克祥,刘星,王守兵.分析国产恩替卡韦分散片治疗慢性乙型肝炎的临床疗效和安全性观察[J].医药前沿,2017,7(32):208-209.
[9]李慧霞.恩替卡韦对慢性乙型肝炎患者抗病毒的临床疗效及其对肝功能指标的影响[J].抗感染药学,2017,14(8):1495-1496.
[2]卢瑜.国产恩替卡韦治疗慢性乙型肝炎患者早期抗病毒疗效分析[J].中国现代药物应用,2017,11(14):107-108.
[3]刘倩,常树珍,崔速南,等.恩替卡韦对核苷类药物经治慢性乙型病毒性肝炎患者的抗病毒疗效观察[J].新医学,2017,48(3):184-187.
[4] Li W, Wang L, Liu Y, et al. Efficacy of entecavir-based rescue therapy in lamivudine-resistant chronic hepatitis B patients in China:a retrospective study[J].Die Pharmazie,2018, 73(4):223.
[5]杨冬冬.阿德福韦酯与恩替卡韦治疗HBeAg阳性慢性乙型肝炎患者临床疗效观察[J].基层医学论坛,2017,21(8):934-935.
[6]段文文,唐芙爱,卢高峰,等.恩替卡韦治疗HBeAg阴性与HBeAg阳性慢乙肝和肝硬化感染患者疗效观察[J].中国地方病防治杂志,2016,25(6):718-720.
[7]康海燕,王艳,耿惠杰,等.国产恩替卡韦治疗代偿期乙肝肝硬化患者的疗效及经济学价值研究[J].现代中西医结合杂志,2016,25(12):1333-1335.
[8]张克祥,刘星,王守兵.分析国产恩替卡韦分散片治疗慢性乙型肝炎的临床疗效和安全性观察[J].医药前沿,2017,7(32):208-209.
[9]李慧霞.恩替卡韦对慢性乙型肝炎患者抗病毒的临床疗效及其对肝功能指标的影响[J].抗感染药学,2017,14(8):1495-1496.